Immune-related Adverse Events: Overview and Management Strategies for the Use of Immune Checkpoint Inhibitors
Journal of Rheumatic Diseases
;
: 221-234, 2019.
Artículo
en Inglés
| WPRIM
| ID: wpr-766195
ABSTRACT
Recent studies on T cell immunology have been instrumental in developing therapies to overcome cancer immune escape, and immune checkpoint inhibitors have emerged as one of the most promising therapeutic tools in advanced cancer patients. Immune checkpoint inhibitors (ICPIs) are monoclonal antibodies that modulate the effects of immune checkpoints. These include cytotoxic T lymphocyte antigen 4 and programmed cell death protein 1, which are co-inhibitory signals responsible for immune suppression. Despite their clinical benefits, ICPIs behave as general immune activators, exerting to several toxic effects called immune-related adverse events attributed to organ-specific inflammation. Here, we review ICPI toxicities, highlighting the importance of their early identification and proper management.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Asunto principal:
Naciones Unidas
/
Muerte Celular
/
Corticoesteroides
/
Alergia e Inmunología
/
Antígeno CTLA-4
/
Inflamación
/
Anticuerpos Monoclonales
Límite:
Humanos
Idioma:
Inglés
Revista:
Journal of Rheumatic Diseases
Año:
2019
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS